NTRK3
NT-3 growth factor receptor
As of the edition of 20 October 2026, NTRK3 (NT-3 growth factor receptor, UniProt Q16288) has 10 drugs tested at it and 13 companies on the list, 2 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16288
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Cancer; Lungs and airways; Nervous system; Eye; Blood and lymph; Digestive system; Immune system; Skin and connective tissue
- Registered trials of its drugs
- 127
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Went quiet | 1 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Entrectinib | Marketed | Phase 4 | Ends 2037 |
| Cenegermin | Marketed | Phase 4 | Ends 2030 |
| Larotrectinib | Marketed | Phase 4 | Ends 2036 |
| Repotrectinib | Marketed | Phase 3 | Ends 2036 |
| Taletrectinib | Marketed | Phase 3 | Ends 2033 |
| Nerve growth factor | Stopped | Phase 4 | none listed |
| Selitrectinib | Status not established | Phase 1 | none listed |
| AZD-6918 | Stopped | Phase 1 | none listed |
| AZD-7451 | Went quiet | Phase 1 | none listed |
| Altiratinib | Stopped | Phase 1 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| AstraZeneca | Route A |
| Bayer | Route B |
The other 10 companies at NTRK3
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at NTRK3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.